Publication:
Elevated tissue expression of RANKL and RANK is associated with poorer survival rates in pancreatic cancer patients

Simple item page
dc.contributor.authorOrtega, Miguel A
dc.contributor.authorJiménez Álvarez, Laura
dc.contributor.authorFraile Martinez, Oscar
dc.contributor.authorGarcia Montero, Cielo
dc.contributor.authorLeon Oliva, Diego De
dc.contributor.authorToledo Lobo, M. Val
dc.contributor.authorPalacios, Esther
dc.contributor.authorGranado, Paula
dc.contributor.authorEsteban, Alfonso
dc.contributor.authorGuijarro, Luis G.
dc.contributor.authorPekarek, Leonel
dc.contributor.authorAsúnsolo, Ángel
dc.contributor.authorBuján, Julia
dc.contributor.authorGarcía Honduvilla, Natalio
dc.contributor.authorÁlvarez Mon, Melchor
dc.contributor.authorSaez, Miguel A
dc.contributor.authorDíaz Pedrero, Raúl
dc.contributor.authorLópez González, Laura
dc.date.accessioned2024-09-05T09:24:03Z
dc.date.available2024-09-05T09:24:03Z
dc.date.issued2024
dc.description.abstractPancreatic cancer is a highly lethal malignancy with a growing incidence reported worldwide. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, which is often diagnosed at advanced stages, making its prognosis and medical management difficult. The identification of histopathological biomarkers has allowed a more precise stratification of pancreatic cancer patients, providing additional information about their prognosis and offering possible therapeutic targets to be explored. The prognostic value of the receptor activator of nuclear factor-kappa B (RANK) and its ligand (RANKL) has been evaluated in breast and prostate tumors, however, their usefulness has not been assessed in pancreatic cancer. In the present work, we analyzed the relationship between the protein expression of RANK and RANKL with the survival of 41 patients with pancreatic cancer followed for 60 months, by performing immunohisto-chemistry and Kaplan-Meier curves. Our results demonstrate a direct association of high expression levels of RANK and RANKL with poorer survival of pancreatic cancer patients in comparison to those with low/medium and null expression levels of both markers. Further studies should be conducted to explore the carcinogenic role of both components in this type of tumor, as well as additional promising translational uses.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.identifier.citationHistology and Histopathology Vol. 39, nº9 (2024)
dc.identifier.doihttps://doi.org/10.14670/HH-18-700
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/143578
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPancreatic adenocarcinomaes
dc.subjectReceptor activator of nuclear factor-kappa B (RANK)es
dc.subjectReceptor activator of nuclear factor-kappa B ligand (RANKL)es
dc.subjectCancer survivales
dc.subjectPrognostic biomarkerses
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titleElevated tissue expression of RANKL and RANK is associated with poorer survival rates in pancreatic cancer patientses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
relation.isAuthorOfPublication4966060f-7ed6-4388-9345-c39bc5f3afe5
relation.isAuthorOfPublication.latestForDiscovery4966060f-7ed6-4388-9345-c39bc5f3afe5
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ortega-39-1133-1140-2024.pdf
Size:
619.34 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.39, nº9 (2024)